Full-Time

Associate Contracts Pricing & Trade Director

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

Compensation Overview

$170.4k - $246.8kAnnually

+ Annual Bonus + Equity Incentive Program

Senior, Expert

San Diego, CA, USA

Category
Financial Planning and Analysis (FP&A)
Risk Management
Finance & Banking
Required Skills
Data Analysis

You match the following Neurocrine Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS/BA degree in business or science Fields and 10+ years of experience in healthcare/pharma; ophthalmic and/or biopharma launch experience and operations and analytics strongly preferred OR
  • Master's degree or MBA preferred and 8+ years of related experience
  • Anticipate business and industry issues; recommend relevant process / technical / service improvements
  • Demonstrate broad expertise or unique knowledge
  • Excellent communication (verbal/written), presentation, problem-solving, analytical thinking and project management skills
  • Strong mentoring skill and abilities; typically mentors lower-level employees and/or indirect teams
  • See broader picture and longer-term impact on division/company
  • Ability to meet multiple deadlines across a variety of projects/programs, with a high degree of accuracy and efficiency
  • Understand coverage, and payments across all payer types
  • Understand and monitor payer policies and trends that impact the therapeutic area
  • Working knowledge of reimbursement, clinical coding/terminology, managed care, and healthcare policy
  • Ability to build relationships with Managed Care, Trade, and Policy executives
  • Ability to work effectively in a cross-functional matrix environment
  • Good understanding of regulatory, legal, compliance requirements for success
  • Skilled at negotiating with business partners or management and influencing senior level leaders regarding matters of significance to the organization
  • Proficient at creating and communicating a clear vision among team members effectively aligning resources and activities to achieve functional area and/or organizational goals
  • Ability to complete quantitative and qualitative analyses of complex strategic initiatives
  • Knowledge of the business models, influence/impact, and decision drivers of U.S. commercial and government payers and PBM’s as well as channel customers (i.e., pharmacy and distribution, etc.)
  • Understanding of reimbursement methodologies utilized by commercial and government payers under pharmacy benefits
  • Demonstrated ability to effectively communicate complex business challenges and data-driven recommendations to senior leaders
  • Ability to create contracting and pricing tactics to implement strategic goals
  • Innovative and able to invent and create opportunities
  • Ability to work in a quickly shifting and fast paced environment
  • Proficiency in Microsoft Office, Outlook and database applications
Responsibilities
  • Facilitate pricing and execution for INGREZZA and other assets in the pipeline
  • Develop thorough, and meaningful analytics pre and post execution to clearly communicate contract results and performance
  • Contribute to shaping the scope and approach for contracting with access stakeholders, including Pharmacy Channel, Commercial Payers, Government Payers, etc.
  • Handle the execution and communication aspects of pricing and contracting, including supporting the preparation of materials for pricing committee meetings, communicating pricing and access strategy to the executive committee and other senior leaders, and informing external stakeholders and field personnel as needed
  • Oversee State Price Transparency Reporting to ensure timely completion of government price reporting requirements and compliance with state price transparency regulations. Effectively lead and manage vendors and internal stakeholders to achieve this
  • Support Gross-to-Net projection and accrual process: develop and run reports from the projection model, perform analysis, and collaborate on accruals
  • Support internal and external audits
  • Stay informed about the market access and health policy landscapes, understanding key legislative policies like the Inflation Reduction Act (IRA), and staying abreast of payer and access stakeholder evolution, pricing, and payment changes that could impact Neurocrine
  • Develop key actionable insights via conceptualizing complex data into concise and actionable insights from access customer (Specialty Pharmacy, Specialty Distributor, Long Term Care Specialty Pharmacy, etc.)
  • Develop insights, strategies, and tactics for market access to include, but not limited to: coverage dashboards and payer team performance metrics
  • As required, attend Field Sales and other company meetings, industry conferences, and customer meetings to stay current on the competitive environment, challenges, and other relevant issues
  • Other duties as assigned
Desired Qualifications
  • Ophthalmic and/or biopharma launch experience and operations and analytics strongly preferred
  • Master's degree or MBA preferred
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY launch positions Neurocrine as a leader in niche markets with high unmet needs.
  • $500 million share repurchase indicates strong financial health and growth confidence.
  • Collaboration with Nxera Pharma could lead to innovative treatments for schizophrenia and dementia.

What critics are saying

  • Increased competition in neuropsychiatric drugs may impact Neurocrine's market share.
  • Potential delays in osavampator's Phase 3 program could affect market entry timeline.
  • Dependence on CRENESSITY's success in the U.S. market poses sales and reputation risks.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on first-in-class treatments for rare disorders like CAH.
  • Strategic collaboration with Takeda enhances Neurocrine's psychiatric disorder portfolio.
  • Partnership with PANTHERx Rare ensures specialized support for CRENESSITY distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

PR Newswire
Feb 21st, 2025
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes U.S

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda

PR Newswire
Jan 21st, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today In The Journal Of Clinical Endocrinology Metabolism

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH."Our understanding of the genetics, pathophysiology, and complications of CAH has exploded over the last 20 years," said Dr. Richard Auchus, M.D., Ph.D., Principal Investigator, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan

ForexTV
Jan 14th, 2025
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Nxera for the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

PR Newswire
Jan 6th, 2025
Neurocrine Biosciences To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com